What Is Noopept?
Noopept (GVS-111) is a synthetic dipeptide nootropic developed in Russia in the 1990s as an improved successor to piracetam — the original racetam and the compound that effectively launched the modern nootropic category. Where piracetam requires doses of 1,600–4,800 mg to produce cognitive effects, Noopept achieves comparable and arguably superior results at 10–30 mg — a roughly 1,000-fold potency advantage.
Developed by pharmaceutical chemist Valentina Gudasheva at the Zakusov Institute of Pharmacology in Moscow, Noopept was designed as a dipeptide prodrug: a molecule that, after oral administration, is cleaved in the gut and liver to release its active metabolite, cycloprolylglycine (CPG) — an endogenous neuropeptide with memory-enhancing properties. This prodrug strategy gave Noopept excellent oral bioavailability and blood-brain barrier penetration that direct administration of CPG cannot achieve.
Noopept is registered as a pharmaceutical drug in Russia (for cognitive impairment associated with organic brain disease) and has been studied in multiple controlled clinical trials. In most Western countries it occupies a gray area — not approved as a drug, not a controlled substance, widely sold as a supplement or research compound.
For the biohacking community, Noopept occupies a unique and valuable position: it is the most studied and most accessible entry point into peptide-based cognitive enhancement. Its oral administration, low dose, strong safety profile, and genuine cognitive efficacy make it the natural starting compound for anyone new to this space before exploring intranasal or injectable options.
Mechanism of Action
Noopept's mechanism is multifaceted and well-studied relative to most research peptides, with several peer-reviewed mechanisms firmly established.
Prodrug to Cycloprolylglycine (CPG): After oral ingestion, Noopept is hydrolyzed to release cycloprolylglycine — an endogenous dipeptide that appears to be the primary active moiety. CPG is itself a neuropeptide with cognitive-enhancing properties, and Noopept's function as a stable, orally bioavailable prodrug for CPG is central to its pharmacology.
AMPA and NMDA Receptor Modulation: CPG and Noopept metabolites modulate both AMPA receptors (involved in fast excitatory transmission and synaptic plasticity) and NMDA receptors (the "coincidence detectors" critical to long-term potentiation and memory formation). This dual glutamate receptor modulation produces a pattern of enhanced synaptic efficiency without the excitotoxic risk of direct NMDA agonism.
Acetylcholine Transmission Enhancement: Noopept increases acetylcholine transmission in the hippocampus and cortex — explaining the critical importance of choline supplementation. Acetylcholine is the neurotransmitter most directly associated with attention, working memory, and memory encoding. Enhanced ACh transmission without adequate choline substrate can produce headache and cognitive fog — the most common Noopept side effect, easily prevented with Alpha-GPC co-supplementation.
BDNF and NGF Expression: Studies demonstrate that Noopept promotes expression of both BDNF and NGF in the hippocampus and cortex, contributing to neuroplasticity beyond its acute receptor-mediated effects. This neurotrophic component helps explain why Noopept's benefits tend to accumulate over a cycle rather than plateauing at the first dose.
Alpha and Beta Brain Wave Enhancement: EEG studies show Noopept increases alpha and beta wave power in cortical regions — waveforms associated with alert, focused cognitive states — while reducing delta and theta activity. This electrophysiological signature is consistent with its reported improvements in verbal fluency and information recall speed.
Key Benefits
Memory Consolidation
Noopept consistently improves the encoding of new information into long-term memory in controlled studies — the effect is most pronounced for information-dense tasks like learning new material, languages, and technical subjects.
Recall Speed
Users reliably report faster retrieval of stored information — names, facts, words — with less "tip of the tongue" frustration. This appears to reflect improved hippocampal indexing efficiency.
BDNF & NGF Elevation
Noopept promotes both BDNF and NGF expression, providing a neurotrophic layer that supports neuroplasticity beyond its acute receptor actions — effects that accumulate over the cycle.
Verbal Fluency
One of the most consistently reported subjective effects — words come faster, sentences form more easily, and verbal communication feels less effortful. Consistent with the alpha/beta wave enhancement observed in EEG studies.
Focus & Attention
Enhanced acetylcholine transmission in the prefrontal cortex produces improved sustained attention and reduced distractibility during cognitive tasks.
Anxiety Reduction (Low Doses)
At lower doses (10–15 mg), many users report a mild anxiolytic effect — possibly related to CPG's modulation of GABA and neuropeptide systems. At higher doses, this may reverse to mild stimulation in sensitive individuals.
Dosing & Protocol
| Experience Level | Daily Dose | Timing | Notes |
|---|---|---|---|
| Beginner | 10 mg | Morning + optional midday | Split into 2 × 5 mg or single 10 mg |
| Standard | 10–20 mg | Morning and/or midday | Avoid dosing after 3 PM |
| Advanced | 20–30 mg | Split across 2–3 doses | Monitor for irritability at 30 mg |
Administration Methods: Oral (swallow with water) or sublingual (dissolve under tongue for faster onset and slightly higher bioavailability). Sublingual administration produces onset within 10–15 minutes. Some users dissolve in a small amount of water for ease of sublingual use.
Cycle Structure: The standard Noopept cycling protocol is 56 days (8 weeks) on, followed by 30 days (4 weeks) off. This longer cycle reflects Noopept's gradual accumulation of neurotrophic effects — benefits continue building through the cycle, and the extended off-period allows receptor resensitization and baseline assessment.
Timing Note: Noopept has mild stimulating properties that can interfere with sleep if dosed too late in the day. The final dose of the day should generally be no later than 2–3 PM. Morning and early afternoon dosing covers the prime cognitive window for most users.
Side Effects & Safety
Noopept has one of the most favorable safety profiles of any cognitive research compound, consistent with decades of clinical research in Russia and widespread global use in the research community.
Irritability at High Doses: At doses above 20–30 mg, some users report mild irritability, over-stimulation, or difficulty relaxing. This is dose-dependent and resolves with dose reduction. It reflects the stimulating action of enhanced glutamate and acetylcholine transmission at the upper dose range.
End-of-Cycle Brain Fog: A minority of users report mild cognitive fog toward the end of a long cycle or when Noopept is discontinued. This typically resolves within a few days of the off-cycle and is considered a normal readjustment period as the neurotrophic effects settle and receptor states normalize.
No Dependence or Withdrawal: Noopept does not produce physical dependence. There is no withdrawal syndrome upon discontinuation. The off-cycle period may simply feel like a return to baseline, which some users find subjectively notable after 8 weeks of enhanced cognition.
Drug Interactions: Noopept should be used with caution alongside psychostimulants (additive effects possible), anticoagulants (theoretical interaction based on some in vitro data), and CNS-active medications. Always review interactions with a physician if you are taking prescribed medications.
Stacking Guide
Noopept's accessible profile and complementary mechanism make it an excellent stack foundation or addition to more complex cognitive protocols.
The Foundation Stack: Noopept (10–20 mg) + Alpha-GPC (300 mg) is the minimum effective stack and the ideal starting configuration. Alpha-GPC is not optional — it is functionally required to prevent the choline-deficiency headache and to fully realize Noopept's acetylcholine-enhancing potential.
The Complete Beginner Cognitive Stack: Noopept (10 mg sublingual, morning) + Alpha-GPC (300 mg) + Selank (250 mcg intranasal, as needed for anxiety or focus depth). This three-component stack addresses glutamate/NMDA plasticity, acetylcholine transmission, and GABAergic anxiety modulation — covering the three primary cognitive performance dimensions accessible to beginner-appropriate compounds.
Advanced Add-on: Adding Semax (300 mcg intranasal) to the Noopept + Alpha-GPC base provides a BDNF layer that complements Noopept's AMPA/NMDA effects for more comprehensive neuroplasticity support.
Build Your Cognitive Stack
Join SDBioHack free to access our stack builder, protocol guides, and member community.
Frequently Asked Questions
Noopept enhances acetylcholine transmission in the brain — it essentially increases the rate at which your neurons use acetylcholine for signaling. Acetylcholine is synthesized from choline, which your body obtains primarily from diet and stores in limited amounts. When Noopept increases ACh turnover, it accelerates choline consumption. If you don't replenish that choline, the result is choline deficiency — which manifests as headache, mental fog, and sometimes irritability. Alpha-GPC is the preferred supplemental choline source because it crosses the blood-brain barrier efficiently and is converted directly to acetylcholine. CDP-choline (citicoline) is also effective. Start at 300 mg Alpha-GPC per day and increase to 600 mg if headaches persist. Do not try to manage Noopept headache by reducing Noopept dose until you've first added adequate choline — the cause is almost always choline deficiency, not Noopept itself.
Both work well, but sublingual administration offers faster onset (10–15 minutes vs 30–45 minutes oral) and slightly higher bioavailability by bypassing first-pass liver metabolism. For timing-sensitive use — dosing 15 minutes before a cognitive task — sublingual is preferable. For convenience and if timing is flexible, oral works fine. Some users find the taste of sublingual Noopept mildly unpleasant (slightly bitter and chemically flavored); dissolving the powder in a small amount of water before holding under the tongue for 60–90 seconds mitigates this. The cognitive effects from both routes are comparable at equivalent absorbed doses.
Noopept was designed as an improved successor to piracetam and is generally regarded as superior on several dimensions. It is roughly 1,000× more potent by mass — 10–30 mg of Noopept achieves what requires 1,600–4,800 mg of piracetam. Noopept additionally produces BDNF and NGF upregulation that piracetam does not, giving it a neurotrophic dimension absent from the original racetam. Both compounds modulate AMPA receptors and glutamate transmission; Noopept's metabolite CPG also engages NMDA receptors more directly than piracetam. Practically, Noopept is easier to dose, cheaper per effective dose, and has a broader mechanism. Piracetam's advantage is its decades-longer history of human use and a correspondingly deeper clinical literature. For most users starting today, Noopept is the better choice.
Key References
- Gudasheva TA, et al. "The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine." European Journal of Drug Metabolism and Pharmacokinetics, 1997.
- Ostrovskaya RU, et al. "The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model." Journal of Psychopharmacology, 2007.
- Neznamov GG, Teleshova ES. "Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin." Neuroscience and Behavioral Physiology, 2009.
- Vorobyov V, et al. "Effects of nootropics on the EEG in awake rats and their modification by glutamatergic inhibition." Brain Research Bulletin, 2011.